Atezolizumab (Tecentriq) and Atezolizumab and Hyaluronidase-tqjs (Tecentriq Hybreza) — CPB 0909 | AETNA Coverage Update

Aetna modified CPB 0909 for atezolizumab (Tecentriq) and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza), effective September 26, 2025. Here's what billing teams need to do.

Aetna, a CVS Health company, updated its atezolizumab coverage policy under CPB 0909 Aetna system, covering HCPCS codes J9022 and J9024 across a broad range of oncology indications. This policy governs precertification requirements, site-of-care rules, and medical necessity criteria for both the IV and subcutaneous formulations of Tecentriq. If your practice bills for checkpoint inhibitor therapy, this update affects your authorization workflow and your documentation requirements before the September 26, 2025 effective date.

Quick-Reference Table

Aetna Atezolizumab Coverage Criteria and Medical Necessity Requirements 2025

The core issue with this Aetna atezolizumab coverage policy is straightforward: precertification is not optional. Aetna requires it for all participating providers and members on applicable plan designs. No precert, no payment — and retroactive authorization won't save a denied claim.

To get precertification for atezolizumab (Tecentriq, J9022), call (866) 752-7021 or fax (888) 267-3277. For the subcutaneous formulation — atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, J9024) — use the same channels or submit a Statement of Medical Necessity form through Aetna's Specialty Pharmacy Precertification portal.

Medical necessity documentation must align with the approved indications covered under this policy. The policy spans an extensive ICD-10 range — over 426 diagnosis codes — covering malignant neoplasms of the lung (C34.x), liver (C22.0), bladder and urinary tract, breast, and many others. That breadth means your team needs to match the specific diagnosis code to the covered indication precisely. A broad-category code that doesn't map to an approved indication is a claim denial waiting to happen.

The Aetna atezolizumab billing guidelines also trigger a site-of-care utilization management review. Aetna's Site of Care policy applies to both formulations. Before you bill 96413, 96414, or 96415 for chemotherapy infusion administration, the site where the infusion occurs must meet Aetna's criteria. Infusions delivered in a higher-cost setting when a lower-cost site was available and appropriate are subject to denial or redirect. This is the same pattern Aetna has used across other specialty infusion drugs — it's a cost-containment lever, not a clinical one, and your team needs to document site justification proactively.

Molecular testing codes appear in this policy — CPT 81235 for EGFR gene analysis, and 88271–88275 for FISH and chromosomal in situ hybridization. These aren't covered codes under CPB 0909 in the primary sense; they're listed as related codes because biomarker testing often drives eligibility for atezolizumab therapy. Accurate biomarker documentation is part of your medical necessity argument. If the test results don't support the indication, the drug authorization won't hold.

Whether Aetna atezolizumab reimbursement holds up on audit depends on the completeness of your precertification file and your diagnosis specificity. Generic "NSCLC" documentation without the specific C34 subcode, or a regimen that includes combination agents like bevacizumab (J9035) or carboplatin (J9045) without separate precertification review, creates exposure.

Coverage Indications at a Glance

Aetna Atezolizumab Billing Guidelines and Action Items 2025

1. Confirm precertification is active before billing J9022 or J9024.
If you don't have an authorization number on file before September 26, 2025, pause new starts until you do. Call (866) 752-7021 for Tecentriq IV or submit an SMN form for Tecentriq Hybreza. Don't assume existing authorizations from prior cycles carry over automatically after the effective date of this modification.

2. Verify site-of-care compliance before billing 96413, 96414, or 96415.
Aetna's Site of Care Utilization Management Policy applies to both Tecentriq formulations. Document why the chosen infusion site — hospital outpatient, physician office, or infusion center — is clinically appropriate. If Aetna determines a lower-cost site was feasible, expect a denial or a reimbursement adjustment. Review Aetna's drug infusion site-of-care UM policy directly and document your justification in the chart.

3. Use the most specific ICD-10-CM code available.
With 426 diagnosis codes in scope, the risk isn't the number of codes — it's using a category-level code when a more specific one exists. C34.10 (right upper lobe NSCLC) is not interchangeable with C34.1 for audit purposes. Your billing team should review the diagnosis coding with the treating oncologist and pull the most granular code the documentation supports.

4. Build a biomarker documentation checklist for every atezolizumab case.
CPT 81235 (EGFR analysis) and 88271–88275 (FISH/in situ hybridization) results belong in your precertification packet. These tests don't just support billing — they're part of what Aetna uses to evaluate medical necessity for the drug authorization. Missing biomarker data is a fast path to a prior authorization denial.

5. Audit combination regimen claims for complete authorization.
Many atezolizumab regimens include carboplatin (J9045), paclitaxel (J9267 or J9264), bevacizumab or its biosimilars (J9035, Q5107, Q5118, Q5126, Q5129), cisplatin (J9060), or oxaliplatin (J9263). Each agent in the regimen may require its own authorization review. Don't assume the atezolizumab auth covers the whole regimen. Check each HCPCS code individually.

6. Separate atezolizumab from other checkpoint inhibitors in your charge capture.
This policy covers J9022 and J9024 specifically. Pembrolizumab (J9271), nivolumab (J9299), durvalumab (J9173), avelumab (J9023), and cemiplimab (J9119) are listed as related agents — but they fall under separate coverage policies. Billing the wrong checkpoint inhibitor code against a CPB 0909 authorization won't work. Your charge capture setup needs to keep these codes distinct.

7. Talk to your compliance officer if your plan mix includes self-insured accounts.
Aetna's clinical policy applies to commercial medical plans. Self-insured employers that use Aetna for administration may have carved-out benefits or different precertification rules. If a significant share of your Aetna volume is ASO business, loop in your compliance officer before assuming CPB 0909 applies uniformly across all accounts.

CPT, HCPCS, and ICD-10 Codes for Atezolizumab Under CPB 0909

Covered HCPCS Codes (When Selection Criteria Are Met)

Key ICD-10-CM Diagnosis Codes

The full ICD-10 list under CPB 0909 contains 426 codes. The ranges above represent the primary diagnostic categories. Use the most specific subcode available for each patient encounter.